{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:41Z","timestamp":1740144041482,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40256-020-00419-9","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T06:03:36Z","timestamp":1592892216000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-3717","authenticated-orcid":false,"given":"Ning","family":"Rosenthal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Kartashov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9e","family":"Levorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimal R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"issue":"9","key":"419_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1164\/rccm.201109-1745CI","volume":"185","author":"E Braunwald","year":"2012","unstructured":"Braunwald E. Unstable angina and non-ST elevation myocardial infarction. Am J Respir Crit Care Med. 2012;185(9):924\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2 Suppl","key":"419_CR2","first-page":"S36","volume":"15","author":"DM Kolansky","year":"2009","unstructured":"Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009;15(2 Suppl):S36\u201341.","journal-title":"Am J Manag Care"},{"issue":"12","key":"419_CR3","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137(12):e67\u2013492.","journal-title":"Circulation"},{"issue":"7","key":"419_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJM199708143370702","volume":"337","author":"M Cohen","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"419_CR5","first-page":"45","volume":"292","author":"JJ Ferguson","year":"2004","unstructured":"Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45\u201354.","journal-title":"JAMA"},{"issue":"2","key":"419_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0002-8703(03)00179-0","volume":"146","author":"LK Michalis","year":"2003","unstructured":"Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J. 2003;146(2):304\u201310.","journal-title":"Am Heart J"},{"issue":"2","key":"419_CR7","first-page":"95","volume":"35","author":"GJ Merli","year":"2010","unstructured":"Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P & T. 2010;35(2):95\u2013105.","journal-title":"P & T."},{"issue":"16","key":"419_CR8","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147\u2013239.","journal-title":"J Am Coll Cardiol"},{"key":"419_CR9","unstructured":"Premier Healthcare Database White Paper: Data that informs and performs, July 29, 2018. Premier Applied Sciences\u00ae, Premier Inc. https:\/\/learn.premierinc.com\/white-papers\/premier-healthcare-database-whitepaper. Accessed Nov 2018."},{"key":"419_CR10","unstructured":"Rosenthal NA, Cao Z, Chung J, et al. Updated coding algorithm for assessing Charlson Comorbidity Index using large hospital administrative data. In: Presented at the 2017 ISPOR Annual Conference on 21 May 2017; Boston, MA."},{"key":"419_CR11","unstructured":"M Health Information Systems. All Patient Refined Diagnosis Related Groups (APR-DRGs) Methodology Overview, Version 20.0. 2003. https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nis\/APR-DRGsV20MethodologyOverviewandBibliography.pdf. Accessed 30 Oct 2017."},{"issue":"5b","key":"419_CR12","doi-asserted-by":"publisher","first-page":"19l","DOI":"10.1016\/S0002-9149(98)00108-8","volume":"82","author":"M Cohen","year":"1998","unstructured":"Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. AM J Cardiol. 1998;82(5b):19l\u201324l.","journal-title":"AM J Cardiol."},{"issue":"3","key":"419_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1067\/mhj.2002.126115","volume":"144","author":"M Cohen","year":"2002","unstructured":"Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J. 2002;144(3):470\u20137.","journal-title":"Am Heart J"},{"issue":"9","key":"419_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.amjcard.2013.07.003","volume":"112","author":"JP Collet","year":"2013","unstructured":"Collet JP, Huber K, Cohen M, et al. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). An J Cardiol. 2013;112(9):1367\u201372.","journal-title":"An J Cardiol"},{"issue":"17","key":"419_CR15","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1161\/01.CIR.97.17.1702","volume":"97","author":"DB Mark","year":"1998","unstructured":"Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation. 1998;97(17):1702\u20137.","journal-title":"Circulation."},{"key":"419_CR16","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1136\/bmj.e553","volume":"344","author":"J Silvain","year":"2012","unstructured":"Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ (Clin Res Ed). 2012;344:e553.","journal-title":"BMJ (Clin Res Ed)."},{"key":"419_CR17","unstructured":"Nie S. Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI (RIGHT). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03664180. Accessed 25 May 2020"},{"issue":"4\u20135","key":"419_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.pcad.2018.01.004","volume":"60","author":"M Zeitouni","year":"2018","unstructured":"Zeitouni M, Kerneis M, Nafee T, Collet JP, Silvain J, Montalescot G. Anticoagulation in Acute coronary syndrome-state of the art. Prog Cardiovasc Dis. 2018;60(4\u20135):508\u201313.","journal-title":"Prog Cardiovasc Dis"},{"issue":"8","key":"419_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/00325481.2015.1092374","volume":"127","author":"KP Kline","year":"2015","unstructured":"Kline KP, Conti CR, Winchester DE. Historical perspective and contemporary management of acute coronary syndromes: from MONA to THROMBINS2. Postgrad Med. 2015;127(8):855\u201362.","journal-title":"Postgrad Med"},{"issue":"6","key":"419_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40256-015-0131-6","volume":"15","author":"Z Fanari","year":"2015","unstructured":"Fanari Z, Weiss S, Weintraub WS. Cost effectiveness of antiplatelet and antithrombotic therapy in the setting of acute coronary syndrome: current perspective and literature review. Am J Cardiovasc Drugs. 2015;15(6):415\u201327.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"24","key":"419_CR21","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139\u2013228.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"419_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5603\/KP.2018.0041","volume":"76","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Kardiol Polska. 2018;76(2):229\u2013313.","journal-title":"Kardiol Polska."},{"issue":"Suppl T","key":"419_CR23","doi-asserted-by":"publisher","first-page":"T23","DOI":"10.4244\/EIJV10STA5","volume":"10","author":"S Windecker","year":"2014","unstructured":"Windecker S, Hernandez-Antolin RA, Stefanini GG, Wijns W, Zamorano JL. Management of ST-elevation myocardial infarction according to European and American guidelines. EuroIntervention. 2014;10(Suppl T):T23\u201331.","journal-title":"EuroIntervention."},{"issue":"24","key":"419_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"GN Levine","year":"2011","unstructured":"Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):44\u2013122.","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00419-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00419-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00419-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T23:24:57Z","timestamp":1624404297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00419-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00419-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"23 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ning Rosenthal and Alex Kartashov are employed by Premier; Zhimin Xiao and Andr\u00e9e Levorsen are employees and stockholders of Sanofi; and Bimal R. Shah served as a subject matter expert through consulting services to Premier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}